Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1151397 | 1.00 | GLP1R (1.00) | GLP1RAMY1A | |
| SCHEMBL3293485 | 1.00 | GLP1R (1.00) | GLP1RAMY1A | |
| SCHEMBL1151245 | 1.00 | GLP1R (1.00) | GLP1RAMY1A | |
| SCHEMBL1151471 | 1.00 | GLP1R (1.00) | GLP1RAMY1A | |
| SCHEMBL1151988 | 1.00 | GLP1R (1.00) | GLP1RAMY1A | |
| SCHEMBL12798935 | 1.00 | GLP1R (1.00) | GLP1RAMY1A | |
| SCHEMBL20237382 | 1.00 | GLP1R (1.00) | GLP1RAMY1A | |
| SCHEMBL1151242 | 1.00 | GLP1R (1.00) | GLP1RAMY1A | |
| SCHEMBL1151480 | 1.00 | GLP1R (1.00) | GLP1RAMY1A | |
| SCHEMBL13590579 | 1.00 | GLP1R (1.00) | GLP1RAMY1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120813-B2 | Oxadiazoanthracene compounds for the treatment of diabetes | VTV THERAPEUTICS LLC (US) | 2015-09-01 | — | — | US | claimed |
| US-20150087640-A1 | Oxadiazoanthracene Compounds for the Treatment of Diabetes | VTV THERAPEUTICS LLC | 2015-03-26 | — | — | US | claimed |
| US-8703766-B2 | Oxadiazoanthracene compounds for the treatment of diabetes | TRANSTECH PHARMA, LLC (US) | 2014-04-22 | — | — | US | claimed |
| US-20130317015-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2013-11-28 | — | — | US | claimed |
| US-8524708-B2 | Oxadiazoanthracene compounds for the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2013-09-03 | — | — | US | claimed |
| US-7906507-B2 | Oxadiazoanthracene compounds for the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2011-03-15 | — | — | US | claimed |
| US-20110039837-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2011-02-17 | — | — | US | claimed |
| US-20100324033-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2010-12-23 | — | — | US | claimed |
| US-7790714-B2 | treating non-insulin dependent diabetes comprising administering a glucagon-like peptide receptor modulators such as (S)-2-({(S)-6-benzoyl-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl}-amino)-3-(4'-cyano-biphenyl-4-yl)-propionic acid | TRANSTECH PHARMA, INC. (US) | 2010-09-07 | — | — | US | claimed |
| US-20100197677-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2010-08-05 | — | — | US | claimed |
| US-7727983-B2 | Glucagon-like peptide-1 (GLP-1) receptor modulators such as (S)-2-({(S)-6-Benzoyl-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl}-amino)-3-(4'-cyano-biphenyl-4-yl)-propionic acid, used as antidiabetic agents; bioavailability | TRANSTECH PHARMA, INC. (US) | 2010-06-01 | — | — | US | claimed |
| US-9120813-B2 | Oxadiazoanthracene compounds for the treatment of diabetes | VTV THERAPEUTICS LLC (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150087640-A1 | Oxadiazoanthracene Compounds for the Treatment of Diabetes | VTV THERAPEUTICS LLC | 2015-03-26 | — | — | US | disclosed |
| US-8933222-B2 | Oxadiazoanthracene compounds for the treatment of diabetes | TRANSTECH PHARMA, LLC (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140187769-A1 | Oxadiazoanthracene Compounds for the Treatment of Diabetes | TRANSTECH PHARMA, LLC (US) | 2014-07-03 | — | — | US | disclosed |
| US-20100324033-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-7790714-B2 | treating non-insulin dependent diabetes comprising administering a glucagon-like peptide receptor modulators such as (S)-2-({(S)-6-benzoyl-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl}-amino)-3-(4'-cyano-biphenyl-4-yl)-propionic acid | TRANSTECH PHARMA, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100197677-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-7727983-B2 | Glucagon-like peptide-1 (GLP-1) receptor modulators such as (S)-2-({(S)-6-Benzoyl-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl}-amino)-3-(4'-cyano-biphenyl-4-yl)-propionic acid, used as antidiabetic agents; bioavailability | TRANSTECH PHARMA, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20090306063-A1 | Glucagon-like peptide-1 (GLP-1) receptor modulators such as (S)-2-({(S)-6-Benzoyl-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl}-amino)-3-(4'-cyano-biphenyl-4-yl)-propionic acid, used as antidiabetic agents; bioavailability | TRANS TECH. PHARMA. INC. (US) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187769-A1 | Oxadiazoanthracene Compounds for the Treatment of Diabetes | GLP1R, INSR, GPR119 | GLP1R 1/4885AMY1A 240/4885 |
| US-20110039837-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | GLP1R, GPR119, OTC | GLP1R 1/4885AMY1A 158/4885 |
| US-20090306063-A1 | Glucagon-like peptide-1 (GLP-1) receptor modulators such as (S)-2-({(S)-6-Benzoyl-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl}-amino)-3-(4'-cyano-biphenyl-4-yl)-propionic acid, used as antidiabetic agents; bioavailability | GLP1R, GIPR, GCGR | GLP1R 1/4885AMY1A 212/4885 |
| US-20100197677-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | GLP1R, GPR119, OTC | GLP1R 1/4885AMY1A 158/4885 |
| US-20130317015-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | GLP1R, GPR119, OTC | GLP1R 1/4885AMY1A 208/4885 |
| US-20100324033-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | GLP1R, GPR119, OTC | GLP1R 1/4885AMY1A 158/4885 |
| US-20150087640-A1 | Oxadiazoanthracene Compounds for the Treatment of Diabetes | GLP1R, GPR119, OTC | GLP1R 1/4885AMY1A 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.